Fitch Revises AstraZeneca's Outlook to Negative; Affirms at 'A+' - Fitch Research

Fitch Revises AstraZeneca's Outlook to Negative; Affirms at 'A+'

Fitch Revises AstraZeneca's Outlook to Negative; Affirms at 'A+' - Fitch Research
Fitch Revises AstraZeneca's Outlook to Negative; Affirms at 'A+'
Published Dec 11, 2015
1524 words — Published Dec 11, 2015
Price US$ 149.00  |  Buy this Report Now

About This Report

  
Brief Excerpt:

Fitch Revises AstraZeneca's Outlook to Negative; Affirms at 'A+' 11 Dec 2015 12:01 PM (EST) Fitch Ratings-London-11 December 2015: Fitch Ratings has revised UK-based pharmaceutical company AstraZeneca PLC's (AZ) Outlook to Negative from...

  
Report Type:

Press Release

Company(ies)
Ticker(s)
AZN
Format:
HTML HTML
Buy Now

Fitch Research—Fitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.

About the Author


Cite this Report

  
MLA:
Fitch Research. "Fitch Revises AstraZeneca's Outlook to Negative; Affirms at 'A+'" Dec 11, 2015. Alacra Store. May 13, 2025. <http://www.alacrastore.com/fitch-credit-research/Fitch-Revises-AstraZeneca-s-Outlook-to-Negative-Affirms-at-A-996576_pr_frame>
  
APA:
Fitch Research. (). Fitch Revises AstraZeneca's Outlook to Negative; Affirms at 'A+' Dec 11, 2015. New York, NY: Alacra Store. Retrieved May 13, 2025 from <http://www.alacrastore.com/fitch-credit-research/Fitch-Revises-AstraZeneca-s-Outlook-to-Negative-Affirms-at-A-996576_pr_frame>
  
US$ 149.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.